On January 21, 2020 Gene Techno Science (Kidswell Bio) reported a joint development agreement with MabGenesis to obtain and apply patent for new antibodies with the effect of killing cancer cells (Press release, Kidswell Bio, JAN 21, 2020, View Source [SID1234625473]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
1. Purpose and background for concluding this agreement
This agreement aims to expand the new pipeline in the new biologic business, which is a future growth driver for our company. Recently, efficiency in cancer treatments has been improved with the emergence of antibody drugs and antibody drug conjugates in addition to conventional small molecule drugs. Furthermore, the realization of antibody drugs with new molecular mechanisms of action, such as Opdivo, has become a long-awaited solution for patients previously considered as untreatable. However, there are still many patients who cannot be cured with those drugs. In fact, R&D for rare and intractable cancers with small number of patients is inactive for financial reasons at present, and therefore development of new cancer treatment is essential.
MabGenesis is a bio venture company aiming to obtain a first-in-class, best-in-class monoclonal antibody using innovative and ingenious antibody isolation technology owned by Professor Kazuhiro Morishita, University of Miyazaki and Lecturer Gene Kurosawa, Fujita Health University. Focusing on this technology, GTS signed a joint research agreement with the aim of executing the development of cancer treatments with a new mechanism of action for rare and intractable cancers by acquiring monoclonal antibodies that bind specifically and firmly to specific antigens expressed on the surface of cancer cells.
2. Contents of this agreement Joint research agreement for acquisition of monoclonal antibodies to specific antigens expressed on the surface of cancer cells
3. Outline of counterparties to this agreement
1. Company Name MabGenesis Inc.
2. Name and title of
representatives
Chief Executive Officer Katsuhiro Shinjo
3. Head Office 1-4, Honcho, Nihonbashi, Chuo-ku, Tokyo
4. Established June 3rd, 2019
5. Main Business Research and development of pharmaceutical drugs
6. Capital 21,750 thousand Japanese Yen
4. Future outlook
The impact on the business results for the fiscal year ending March 2020 is expected
to be minimal.